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Plasminogen/plasmin system is known for its ability to support hemostatic balance of blood. however, 
plasminogen may be considered as an adhesive ligand and in this way could affect the functioning of blood 
cells. We showed that exogenous Lys-plasminogen, but not its Glu-form, inhibited platelet aggregation and 
suppressed platelet α-granule secretion. The aim of this work was to investigate the influence of Glu- and Lys-
form of plasminogen on the formation of platelet procoagulant surface using phosphatidylserine exposure as 
a marker. human platelets were obtained from human platelet-rich plasma (donors were healthy volunteers, 
men aged 30-40 years) by gel-filtration on Sepharose 2B. Phosphatidylserine exposure on the platelet surface 
was evaluated by flow cytometry with FITC-conjugated annexin A5. Glu- and Lys-plasminogen have different 
impact on the platelet functioning. Exogenous Lys-plasminogen has no significant effect on phosphatidylser-
ine exposure, while Glu-plasminogen increases phosphatidylserine exposure on the surface of thrombin- and 
collagen-activated human platelets. Glu-plasminogen can be considered as a co-stimulator of agonist-in-
duced platelet secretion and procoagulant surface formation. Meanwhile effects of Lys-plasminogen are prob-
ably directed at platelet-platelet interactions and not related to agonist-stimulated pro-apoptotic changes. 
The observed different effects of Glu- and Lys-plasminogen on phosphatidylserine exposure can be explained 
by their structural peculiarities.
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P lasminogen/plasmin system plays the key role in degradation of fibrin clots and sup-ports hemostatic balance of blood. However, 
it was reported that plasminogen can be considered 
as an adhesive ligand for integrins and modulate 
functioning of blood cells [1]. There are two forms of 
plasminogen, which differ according to their struc-
ture and functional role in hemostasis system. The 
native form of the molecule, Glu-plasminogen, pos-
sesses closed conformation and it is the main form of 
plasminogen circulating in plasma. Lys-plasminogen 
is a partially degraded form, which is formed due to 
catalytic action of plasmin on Glu-plasminogen. Lys-
plasminogen is not present in blood under physio-
logical conditions but a low amount of this form was 
detected in blood of patients undergoing thrombo-
lytic therapy with tissue plasminogen activator [2]. 
It was shown that Lys-plasminogen has more open 
conformation and possesses more affinity towards 
fibrin and membrane receptors [3]. It is known that 
both forms of plasminogen are able to bind to platelet 
surface, however, Lys-plasminogen binds to platelets 
with higher affinity [4]. In our previous investiga-
tions, we showed that exogenous Lys-plasminogen 
inhibits platelet aggregation and suppresses plate-
let α-granule secretion, meanwhile the native form 
of plasminogen has no significant influence on the 
above-mentioned processes [5, 6]. We suggested 
that plasminogen effects, which were shown during 
platelet aggregation and secretion, can be observed 
at the step of procoagulant phospholipid membrane 
formation, i.e. phosphatidylserine exposure on the 
platelet surface. The present work is aimed to study 
plasminogen influence on phosphatidylserine expo-
sure on the surface of platelets activated by thrombin 
or collagen.
materials and methods
Plasminogen preparation. Glu-plasminogen 
was purified from fresh blood plasma of healthy 
volunteers and Lys-plasminogen was isolated from 
Cohn fraction III2,3. Research protocols were ap-
doi: https://doi.org/10.15407/ubj89.si01.102
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proved by the Ethical Committee of Palladin Insti-
tute of Biochemistry of NASU (from 3rd of Novem-
ber 2014, protocol N 10).
Lysine-sepharose chromatography was used 
in both cases [7]. All preparations of plasminogen 
had no spontaneous plasmin activity. Plasminogen 
preparations in all experiments were used at final 
concentration 1.2 µM.
Platelet aggregation. Intact platelets were ob-
tained from human platelet-rich plasma by gel-filtra-
tion on Sepharose 2B [8]. Platelet aggregation was 
measured by optical aggregometry (aggregometer 
Solar AT-02, Belorussia). All assays were performed 
within 60-80 min after platelet collection. Thrombin 
(Sigma Aldrich, USA) at final concentration 1 unit 
NIH/ml and collagen (Tekhnologia Standard , Rus-
sia) at final concentration 1.25 mg/ml were used to 
stimulate platelets. Experimental data were statisti-
cally analyzed using software MS Office Excel 2007 
and Agregometr 2.01.
Flow cytometry. To investigate plasminogen 
effects on phosphatidylserine exposure flow cytom-
etry with FITC-conjugated annexin A5 (Sigma Al-
drich, USA) was used. Washed platelets (2.5×106) 
were transferred into 100 µl of 20 mM HEPES 
buffer , pH 6.8, containing 137 mM NaCl, 4 mM 
KCl, 0.2 mM MgCl2, 0.2% glucose and 0.2% BSA. 
The platelets were incubated with Glu- or Lys-plas-
minogen for 3 min at 22-25 ºC with or without fur-
ther incubation with thrombin or collagen for 5 min 
at 22-25 ºC. Intact platelets were served as control. 
After incubation, platelets were washed by 0.05 M 
PBS, pH 7.4, with 0.13 M NaCl by centrifugation 
at 1,000 g at 25 ºC. Platelets were resuspended in 
1.5 ml of 0.05 M PBS, pH 7.4, with 0.13 M NaCl, 
according with manufacturer’s instruction. FITC-
conjugated annexin A5 was added to all samples and 
suspension was incubated in the darkness at room 
temperature for 30 min. Fluorescence intensity was 
monitored by Coulter Epics flow cytometer (Beck-
man Coulter, USA) via FL1 channel (515-535 nm). 
Annexin A5 exposure on the platelet surface was 
estimated using two parameters: 1) the percentage 
of annexin A5-positive cells of total cell number in 
the sample 2) the fluorescence intensity which was 
detected via FL1 channel (515-535 nm). To obtain 
statistically significant results no less than 15,000 
events were analyzed for each sample. The measure-
ment of cytometric parameters in each group of cells 
was carried out in duplicate, and the mean value was 
calculated based on the values obtained from all do-
nors. 
The results were graphically presented using 
“FCS Express V3” (De Novo Software, USA). The 
data were expressed as mean ± SD. Statistical analy-
sis of the results was performed with using of Stu-
dent’s t-test, the difference was considered as signifi-
cant at P < 0.05.
results and discussion
For better presentation of flow cytometry re-
sults two gated regions were created. Gated region 
M1 was set to estimate the population of annexin 
A5-positive platelets and M2 marker was crea-
ted around the clearly identifiable sub-population 
showing high level of annexin A5 binding. (Fig. 1). 
We found that among intact platelets there was only 
small amount of cells exposing phosphatidylserine 
on their surface (3.6 ± 1.3%), see Fig. 2. Thrombin 
stimulation (1 unit NIH/ml) increased the amount of 
annexin A5 positive cells in 8.6 times (31 ± 3.9%). 
It has to be noted that large proportion of the plate-
lets (2/3) displayed high level of annexin A5 binding . 
Framing such sub-population during thrombin ac-
tivation was shown at the dot graph (see Adden-
dum 1): dot density was significantly shifted on the 
right by axis FL1 LOG, indicating the high fluores-
cence intensity of thrombin-stimulated platelets. The 
average fluorescence of this sub-population was 1.5-
2 times higher than in the whole population of an-
nexin A5-positive cells. Thrombin stimulation led to 
phosphatidylserine exposure and as a result annexin 
A5 binding on the platelet surface. The proportion 
of annexin A5-positive platelets became larger and 
it was noticed the appearance of sub-population of 
platelets with intensive fluorescence.
Incubation with Glu-plasminogen followed 
by thrombin stimulation resulted in the increase of 
population of annexin A5-positive platelets (in 1.6 
times). Under these conditions, the effect of Lys-
plasminogen was more moderate. In case of Lys-
plasminogen effect, the changes were related with 
the sub-population of platelets showing low level of 
annexin A5 binding (Addendum 1, group “Lys-Pg 
+ Thr”). It has to be noted that plasminogen itself, 
in the absence of stimulation, had no influence on 
platelet functions.
Collagen was a potent stimulator of phosphati-
dylserine exposure as the amount of annexin A5-
binding platelets increased on 55.3 ± 8.8% (Fig. 3, 
a). Most annexin A5-positive cells possessed high 
fluorescence. The fluorescence intensity of these 
cells was 6 times higher as compared to this one 
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Fig. 1. Thrombin effect on annexin A5 binding by washed human platelets (typical histogram). M1 – popula-
tion of annexin A5-positive platelets, М2 – sub-population of platelets showing high level annexin A5 binding. 
FL1 LOG – the log of FITC-fluorescence intensity: ■ – intact platelets without annexin A5;  – thrombin-
stimulated platelets with added annexin A5;  – intact platelets with added annexin A5
Fig. 2. Effects of Glu- and Lys-plasminogen on annexin A5 exposure on thrombin-stimulated platelets (n = 4). 
M1 – population of annexin A5-positive platelets, М2 – sub-population of platelets showing high level annexin 
A5 binding. Difference in the compared groups is statistically significant (р < 0.05): * compared to the group 
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for population of intact cells (Fig. 3, B). The sub-
population of platelets showing high level of annexin 
A5 binding was framed (Addendum 2, “Collagen”): 
dot density was significantly shifted on the right 
by axis FL1 LOG, indicating the high fluorescence 
intensity of collagen-stimulated platelets. Vertical 
division of annexin A5-positive cells showed the in-
creasing granularity under collagen stimulation. It 
should be noted that the proportion of the platelets 
showing high level of annexin A5 binding was even 
larger (4/5) than in case of thrombin. Pre-incubation 
of platelets with Glu-plasminogen enhanced the 
collagen effect: the number of annexin A5-positive 
platelets was not significantly changed, however, the 
fluorescence intensity of these cells increased at least 
in two times. Incubation with Glu-plasminogen in-
duced the formation of the larger population of plate-
lets showing high level of annexin A5 binding. Lys-
plasminogen under these conditions had no effects.
The relationship between plasminogen binding 
to cells and phosphatidylserine exposure has been 
earlier described in the literature [9-11]. O'Mullane 
et al. showed that in the presence of apoptotic fac-
tors (thrombin is considered as one of them) exo-
genous Glu-plasminogen considerably increases 
phosphatidylserine exposure on the surface of cells 
of monocyte culture U 937 [12]. According to our 
data, thrombin is not only stimulates platelet activa-
Fig. 3. Effects of Glu- and Lys-plasminogen on annexin A5 exposure on collagen-stimulated platelets (n = 3): 
А – amount of annexin A5 positive cells, B – fluorescence intensity. M1 – population of annexin A5-positive 
platelets; М2 – sub-population of platelets showing high level of annexin A5 binding. Difference in the com-
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tion and secretion of α-granules, but also potentiates 
the formation of procoagulant surface. Thrombin 
stimulation led to activation of surface receptors GP 
Ib and IIbIIa and triggers the chain of events which 
leads to the formation of procoagulant surface (see 
Fig. 4). As it was previously shown the inhibition 
of these receptors on the platelet surface by specific 
antibodies blocked the exposure of procoagulant ac-
tivity on platelets [13].
According to our data, Glu-plasminogen can 
be considered as a co-stimulator of agonist-induced 
platelet secretion and procoagulant surface forma-
tion. Effects of Lys-plasminogen are probably di-
rected at platelet-platelet interactions and not related 
to agonist-stimulated pro-apoptotic changes. We 
showed that the stimulating effect of Glu-plasmi-
nogen in exposure of phosphatidylserine was more 
pronounced under thrombin stimulation. It can be 
explained by the fact that these agonists realize their 
stimulating effects through different ways. Dormann 
et al. suggested that in case of thrombin, platelet gly-
coprotein GP Ib plays an essential role in the forma-
tion of platelet procoagulant surface [13]. In case of 
collagen, this glycoprotein is not involved.
The obtained results highlight the possibili ty 
of the practical use of two forms of plasminogen in 
therapeutic practice. As it was noted before, Lys-
plasminogen in complex with streptokinase can be 
considered as a tool for the treatment of patients 
with deep vein thrombosis [14] and administration 
of Glu-plasminogen improves the healing of chronic 
diabetes wounds in a mouse model of diabetes [15]. 
Besides, it was shown that platelets in type 2 diabetic 
individuals adhere to vascular endothelium and ag-
gregate more readily than those in healthy people 
[16]. Lys-plasminogen, which shows its anti-aggre-
gation effect, seems to be a good candidate for cor-
relation of such pathological state. 
In conclusion, the obtained results indicate the 
different effects of Glu- and Lys-plasminogen on 
platelet functions. The precise mechanisms of these 
effects need further investigation and will be clari-
Fig. 4. Thrombin influence on platelet activation and phosphatidylserine exposure. GP Ib – integral platelet 
glycoprotein, PS – phosphatidylserine; IIbIIIa – platelet integrin; adhesive ligands for IIbIIIa: vWf – von 
Willebrand factor, Fg – fibrinogen, Fn – fibronectin
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Addendum 1. Effects of Glu- and Lys-plasminogen on annexin A5 exposure under thrombin stimulation (typi-
cal dot graph): SS LOG – the log side scatter (platelet granularity), FL1 LOG – the log of FITC-fluorescence 
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Addendum 2. Effects of Glu- and Lys-plasminogen on annexin A5 exposure under collagen stimulation (typi-
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fied in the future studies. However, we suggest that 
the conformational differences between native and 
truncated forms of plasminogen molecules could 
play the principal role for realization of above-men-
tioned effects. 
Funding This work was supported by the 
Grant of National academy of Science of Ukraine 
0113U003203.
Glu- та lys-форми 
плазміногену по різному 
впливають на експонування 
фосфатидилсерину на 
поверхні тромбоцитів
Д. Д. Жерносєков, Я. М. рока-
Мойя, A. O. Tихомиров, M. M. Гузик, 
T. В. Гриненко




відає за підтримку гемостатичного балансу 
крові. Водночас плазміноген може виступати як 
адгезивний ліганд і таким чином впливати на 
функціонування клітин крові. Нами було пока-
зано, що екзогенний Lys-плазміноген, на відміну 
від Glu-форми, призводить до інгібування 
тромбоцитарної агрегації та пригнічує секрецію 
α-гранул тромбоцитів. Мета цієї роботи – 
дослідити вплив Glu- та Lys-форм плазміногену 
на формування прокоагулянтної поверхні 
тромбоцитів, використовуючи як маркер екс-
понування фосфатидилсерин на тромбоцитах. 
Тромбоцити отримували зі збагаченої тромбоци-
тами плазми (здорові донори-волонтери, чоловіки 
віком 30–40 років) методом гель-хроматографії 
на сефарозі 2В. Експонування фосфатидил-
серину на поверхні тромбоцитів оцінювали 
методом протокової цитофлуориметрії за до-
помогою ФІТЦ-кон’югованого анексину А5. 
Показано, що Glu- та Lys-форми плазміногену 
спричиняли різний вплив на функціонування 
тромбоцитів. Екзогенний Lys-плазміноген не 
мав істотного впливу на експонування фос-
фатидилсерину, в той час як Glu-плазміноген 
за цих умов призводив до підвищеного ек-
спонування фосфатидилсерину на поверхні 
тромбоцитів активованих тромбіном або кола-
геном. Зроблено висновок щодо можливої ролі 
Glu-плазміногену як ко-стимулятора агоніст-
індукованої секреції тромбоцитів, так і стиму-
лятора формування прокоагулянтної поверхні. 
Ефекти Lys-плазміногену ймовірно спрямовані 
на міжтромбоцитарну взаємодію і не пов'язані 
з агоніст-стимульованими про-апоптичними 
змінами.  Різний ефект Glu- та Lys- форм 
плазміногену може бути пояснений структурни-
ми особливостями відповідних форм зимогену. 
K л ю ч о в і  с л о в а: Glu- та Lys-
плазміноген, експонування фосфатидилсерину, 
тромбоцити.
Glu- и lys-формы 
плазминогена оказывают 
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Плазминоген/плазминовая система отве-
чает за поддержание гемостатического баланса 
крови. В то же время плазминоген может вы-
ступать в роли адгезивного лиганда и таким 
образом влиять на функционирование клеток 
крови. Нами было показано, что экзогенный 
Lys-плазминоген, в отличие от Glu-формы, 
способствует ингибированию тромбоцитар-
ной агрегации и подавляет секрецию α-гранул 
тромбоцитов. Цель настоящей работы – иссле-
довать влияние Glu- и Lys-формы плазминогена 
на формирование прокоагулянтной поверхно-
сти тромбоцитов, используя в качестве маркера 
экспонирование фосфатидилсерина на тромбо-
цитах. Тромбоциты получали из обогащенной 
тромбоцитами плазмы (здоровые доноры-до-
бровольцы, мужчины 30–40 лет) методом гель-
хроматографии на сефарозе 2В. Экспонирование 
фосфатидилсерина на поверхности тромбоци-
тов оценивали методом проточной цитофлуо-
риметрии с помощью ФИТЦ-конъюгированного 
аннексина А5. Показано, что, Glu- и Lys-формы 
плазминогена проявляли разный эффект на 
функционирование тромбоцитов. Экзогенный 
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Lys-плазминоген не оказывал существенного 
влияния на экспонирование фосфатидилсери-
на, в то время как Glu-плазминоген в этих ус-
ловиях приводил к повышению уровня экспо-
нированного фосфатидилсерина на поверхности 
тромбоцитов активированных тромбином или 
коллагеном. Сделали вывод о возможной роли 
Glu-плазминогена как ко-стимулятора аго-
нист-индуцированной секреции тромбоцитов и 
стимулятора формирования прокоагулянтной 
поверхности. Эффекты Lys-плазминогена веро-
ятно направлены на межтромбоцитарные вза-
имодействия и не связаны с агонист-стимули-
рованными про-апоптическими изменениями. 
Разный эффект Glu- и Lys- форм плазминогена 
может быть объяснен структурными особенно-
стями соответствующих форм зимогена.




1. Lishko VK, Novokhatny VV, Yakubenko VP, 
Skomorovska-Prokvolit HV, Ugarova TP. 
Characterization of plasminogen as an adhesive 
ligand for integrins alphaMbeta2 (Mac-1) and 
alpha5beta1 (VLA-5). Blood. 2004; 104(3): 719-
726.
2. Holvoet P, Lijnen HR, Collen D. A monoclonal 
antibody specific for Lys-plasminogen. 
Application to the study of the activation 
pathways of plasminogen in vivo. J Biol Chem. 
1985; 260(22): 12106-12111.
3. Miles LA, Castellino FJ, Gong Y. Critical 
role for conversion of glu-plasminogen to 
Lys-plasminogen for optimal stimulation of 
plasminogen activation on cell surfaces. Trends 
Cardiovasc Med. 2003; 13(1): 21-30. 
4. Miles LA, Dahlberg CM, Plow EF. The cell-
binding domains of plasminogen and their 
function in plasma. J Biol Chem. 1988; 263(24): 
11928-11934.
5. Tykhomyrov AA, Zhernossekov DD, Roka-
Moya YM., Diordieva SI, Grinenko TV. The 
effects of Lys-plasminogen on human platelet 
secretion. Fiziol Zhurn. 2015; 61(6): 26-34. (In 
Ukranian).
6. Roka-Moya YM, Zhernossekov DD, Grinen-
ko TV. Plasminogen/plasmin influence on 
platelet aggregation. Biopolym Cell. 2012; 28(5): 
352-356.
7. Deutsch DG, Mertz ET. Plasminogen: purification 
from human plasma by affinity chromatography. 
Science. 1970; 170(3962): 1095-1096.
8. Kruger LA, Barnard MR, Frelinger AL III, 
Furman ML, Michelson AD. Immunophenotypic 
analysis of platelets. Current protocols in 
cytometry. New York, John Wiley and Sons; 
2002.
9. Zhernossekov DD, Roka-Moiia YM, Grinen-
ko TV. Extracellular annexins in hemostasis 
system. Biopolym Cell. 2016; 32(2): 98-104.
10. Whyte CS, Swieringa F, Mastenbroek TG, 
Lionikiene AS, Lancé MD, van der Meijden PE, 
Heemskerk JW, Mutch NJ. Plasminogen 
associates with phosphatidylserine-exposing 
platelets and contributes to thrombus lysis under 
flow. Blood. 2015; 125(16): 2568-2578.
11. Das R, Plow EF. Phosphatidylserine as an anchor 
for plasminogen and its plasminogen receptor, 
histone H2B, to the macrophage surface. 
J Thromb haemost. 2011; 9(2): 339-349.
12. O'Mullane MJ, Baker MS. Elevated plasminogen 
receptor expression occurs as a degradative 
phase event in cellular apoptosis. Immunol Cell 
Biol. 1999;7 7(3): 249-255.
13. Dörmann D, Clemetson KJ, Kehrel BE. The 
GPIb thrombin-binding site is essential for 
thrombin-induced platelet procoagulant activity. 
Blood. 2000;96(7): 2469-2478.
14. Kakkar VV, Scully MF. Intermittent 
plasminogen-streptokinase treatment of deep 
vein thrombosis. haemostasis. 1988; 18(Suppl 1): 
27-38.
15. Shen Y, Guo Y, Mikus P, Sulniute R, 
Wilczynska M, Ny T, Li J. Plasminogen is a key 
proinflammatory regulator that accelerates the 
healing of acute and diabetic wounds. Blood. 
2012; 119(24): 5879-5887.
16. Vinik AI, Erbas T, Park TS, Nolan R, 
Pittenger GL. Platelet dysfunction in type 2 
diabetes. Diabetes Care. 2001; 24(8): 1476-1485.
Received 31.01.2017
